Akebia Therapeutics
AKBA
#8132
Rank
A$0.48 B
Marketcap
A$1.80
Share price
-3.08%
Change (1 day)
-69.20%
Change (1 year)

Operating Margin for Akebia Therapeutics (AKBA)

Operating Margin as of July 2026 (TTM): -8.07%

According to Akebia Therapeutics's latest financial reports and stock price the company's current Operating Margin is -8.07%. At the end of 2025 the company had an Operating Margin of -1.58%.

Operating Margin history for Akebia Therapeutics from 2017 to 2026

Operating Margin at the end of each year

Year Operating Margin Change
2025-1.58%-96.36%
2024-43.33%62.42%
2023-26.68%-17.18%
2022-32.22%-75.82%
2021-133.25%2.02%
2020-130.61%52.84%
2019-85.46%3.26%
2018-82.76%103.58%
2017-40.65%-99.54%
2016-8,843.45%

Operating Margin for similar companies or competitors

Company Operating Margin Operating Margin differencediff. Country
Johnson & Johnson
JNJ
34.58%-528.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
27.89%-445.60%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Amgen
AMGN
24.41%-402.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Nektar Therapeutics
NKTR
-273.59% 3,290.21%๐Ÿ‡บ๐Ÿ‡ธ USA

What is a company's Operating Margin?

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.